Seasonal Allergic Rhinitis Study

Asthma Clinical Trial

— SAR  

Official title:

Evaluation of the Effect of Yoghurt-type Drink on Symptoms of Subjects Suffering Seasonal Allergic Rhinitis (SAR) [Rhinitis 2]

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01123252
• Other study ID #: UEA SAR 1
• Status: Completed
• Phase: Phase 2
• First received: May 11, 2010
• Last updated: August 22, 2012
• Start date: September 2010
• Est. completion date: April 2011

Study information

• Verified date: August 2012
• Source: University of East Anglia
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The study aims to examine the effect of probiotics on the clinical symptoms of allergic rhinitis and to elucidate some of the immunological mechanisms involved.

Description:

Epidemiological studies have shown that the incidence of atopic diseases (eczema, food allergy, allergic rhinitis and asthma) has been rising over the last few decades. The rate of increase precludes genetic make-up as the sole cause of the atopic epidemic and implicates environmental factors instead. Currently, allergic rhinitis (hay fever) is one of the world's most common chronic allergic diseases. It affects over 600 million people and often leads to asthma. There are huge costs associated with the condition in terms of both health care and work days lost, with British businesses estimated to lose £324 million this summer alone. For the sufferers, the symptoms severely affect their quality of life. It disturbs their sleep and impairs daytime concentration and performance at work or school. Currently there is no cure for it.

The importance of the gut microbiota in general well-being is evidenced by several experimental observations. It is difficult to achieve oral tolerance in germ-free animals [Sudo et al. 1997] while administration of lipopolysaccharide (a constituent of the outer membrane of gram-negative bacteria) together with food antigens increases the tolerizing effect of feeding [Kim & Ohsawa 1995]. While able to assist in tolerance induction, bacterial products may also break oral tolerance [Gaboriau-Routhiau et al. 1996]. These findings led Wold to suggest in 1998 that an altered normal intestinal colonization pattern in infancy, which fails to induce immunological tolerance, could be responsible for the increase in allergies. Recent studies suggest that the effects of the gut microbiota may not only be related to food antigens, but also to aeroallergens [Noverr et al. 2004, 2005]. Forsythe and his colleagues (2007) managed to attenuate adverse airway responses in a mouse model of allergic asthma through oral administration of probiotics.

The mechanisms by which probiotics exert their effects are unknown at present, but experiments in mice have documented improved gastrointestinal barrier function [Ewaschuk et al. 2008]. Since these experiments have also revealed a strain-dependent heterogeneity in the efficacy of probiotics [N.G. Hord 2008] it is unlikely that improved barrier function alone is responsible for the beneficial effects noted. Given the sheer numbers of microorganisms that inhabit our mucosal surfaces, it is likely that there are normally bidirectional interactions between them and the epithelial, immune, neurologic and endocrine physiological processes initiated by and between them. We hypothesize that a probiotic organism is ingested in sufficient quantities to amplify its particular trait relative to the milieu of other organisms present in relatively lower quantities, temporarily over-riding the diversity present. In that case, the transfer of information between the probiotic organism and cellular components of the gut has particular impact. In order to understand and manipulate this probiotic-mucosa cross-talk towards therapeutic advantage, there is a need to focus on the transfer of information between the microbiota and cellular components of the mucosal immune system.

Few studies have examined the effect of probiotics on allergic rhinitis and the studies that have been performed [Helin et al. 2002; Wang et al. 2004; Xiao et al. 2006] are inconclusive. In our own pilot study we tested the ability of Lactobacillus casei Shirota (LcS) to alter immunological events in seasonal allergic rhinitis (SAR) [Ivory et al. 2008]. The study format was double-blinded and placebo-controlled with ten SAR sufferers in each group. We compared changes in immune status arising through the daily ingestion of a milk drink supplied by Yakult, with or without live LcS, over a period of 5 months. Pre-, peak- and post-grass pollen season blood samples were collected for determination of plasma grass pollen-specific IgG and IgE levels by immunoassay. At the same time, cytokine levels were determined by flow cytometric bead array technology following culture of peripheral blood mononuclear cells for six days in the presence or absence of specific grass pollen antigens. We found that volunteers treated with LcS showed a significant reduction in levels of antigen-induced IL-5, IL-6 and IFN- production compared to volunteers supplemented with placebo. Meanwhile, levels of pollen-specific IgG increased and IgE decreased in the probiotic group. Other changes in cytokine levels were seen but they did not attain statistical significance, most likely due to the small number of volunteers tested. Our work has established for the first time that probiotic supplementation modulates immune responses in allergic rhinitis through down-regulation of both Th1- and Th2-type cytokines and to beneficially alter the balance of pollen-specific IgG and IgE levels in allergic rhinitis subjects. It has also suggested that the impact of probiotics reaches beyond the intestine.

We would now like to conduct another study to show that the immunological changes arising through probiotic consumption have an impact on the clinical symptoms of hay fever. In addition, we propose to elucidate some of the mechanisms involved that may contribute to the health benefit. As far as we know there have not been any similar studies to date. The ability to demonstrate clinical efficacy of dietary intervention for hay fever treatment has obvious benefits for the relevant sufferers. Economic benefits would arise through the relatively inexpensive 'treatment' that would be self-administered and likely lower absenteeism from work. There is also a need for evidence-based viability for the many health claims made for probiotic consumption that could result in clear guidance to the general public.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Men or women over 16 years of age.

• A history of SAR for a minimum of 2 years before study entry.

• Documentation of sensitivity by positive skin testing (by prick or intradermal methods) or by adequately validated in vitro tests for specific IgE (e.g., RAST, PRIST) to grass pollen within 12 months prior to enrolment. If this is not available, appropriate tests will be performed at screening.

• Able to provide written informed consent

Exclusion Criteria:

• Ingestion of probiotics as part of normal diet

• Significant medical, surgical or psychiatric disease that in the opinion of the participants' attending physician would affect subject safety or influence the study outcome.

• Symptoms of rhinitis at screening indicated by total symptom scores of more than 2 out of 12 (based on a combination of nasal symptoms of blockage, sneezing, rhinorrhoea and itching).

• Current smokers or ex-smokers of <1 year or those who have smoked the equivalent of 20 cigarettes/day for 20 years or more.

• Participants receiving any form of corticosteriod from 1 month prior to the study

• Inadequate washout periods for the following:

Intranasal cromolyn (2 weeks) Intranasal or systemic decongestants (3 days) Intranasal or systemic antihistamines (3 days), except astemizole (6 weeks) or loratadine (10 days).

• Documented evidence of acute or significant chronic sinusitis

• A history of hypersensitivity to the milk or its products

• Pregnant women or those planning a pregnancy. It is important not to include pregnant women in the study due to the possibility of miscarriage following anaphylaxis.

• Lactating women are excluded as those infants breast fed by mothers responding to allergenic challenges can transmit the manifestations of allergic responses to the feeding infant via breast milk

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Asthma
• Grass Allergy
• Rhinitis
• Rhinitis, Allergic, Seasonal
• Seasonal Affective Rhinitis

Intervention

Dietary Supplement:
• Lactobacillus casei Shirota (LcS)
Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
• Placebo
Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).

Locations

Country	Name	City	State
United Kingdom	CRTU University of East Anglia	Norwich	Norfolk
United Kingdom	Institute of Food Research	Norwich	Norfolk
United Kingdom	Norfolk and Norwich University Hospital	Norwich	Norfolk
United Kingdom	University of East Anglia	Norwich	Norfolk

Sponsors (4)

Lead Sponsor	Collaborator
University of East Anglia	Institute of Food Research, Norfolk and Norwich University Hospitals NHS Foundation Trust, Yakult Honsha Co., LTD

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total nasal symptom score	Following exposure to allergen, there is an immediate rise in the reported symptoms,the recording of the symptoms scored at various time points is referred to as the TNSS. Participants will be asked to record their symptoms on a 4 point scale, with 0 representing no symptoms and 3 representing maximal symptoms: 0 = absent symptoms; = mild symptoms; = moderate symptoms; = severe symptoms; Symptoms will be recorded under the following: Sneezing / Itching / Rhinorrhoea / Congestion; The individual symptoms will be summed to give a total nasal symptom score.	10 minutes following nasal allergen challenge	No
Secondary	Area under the curve for nasal symptoms scores for 12 hours following nasal allergen challenge		12 hours	No
Secondary	• Area under the curve for peak nasal inspiratory flow for 12 hours following nasal allergen challenge		12 hours	No
Secondary	Phenotype of nasal epithelial cells from scrapings		4 months	No
Secondary	Nasal lavage inflammatory mediator profile		4 months	No